Kate Haggerty, MD
Public Health & General Preventive Medicine · San Marcos, CANPI 1083928337
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Intra-sana Laboratories accounts for 62.8% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $7,197, more than ten times the $216 reported in 2023. Among public health & general preventive medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $364.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intra-sana Laboratories$5K
- RGH Enterprises LLC$2K
- Novo Nordisk$176
- Gilead$126
- Sanofi$122
- Lilly USA, LLC$118
- plus $56 from 2 others
What the payments were for
- Consulting fees$2,25029%
- Speaking & faculty fees$4,50059%
- Food & beverage$90512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intra-sana Laboratories | 8 | $4,806 |
| RGH Enterprises LLC | 4 | $2,250 |
| Novo Nordisk | 4 | $176 |
| Gilead | 1 | $126 |
| Sanofi | 1 | $122 |
| Lilly USA, LLC | 1 | $118 |
| Exact Sciences | 1 | $35 |
| AbbVie | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$4,625
- GLYCATE$4,625
- Reltone 400 Mg$4,625
- DUPIXENT$122
- Wegovy$120
- MOUNJARO$118
How this compares
$7,655 in reported general payments places this provider in the 90th percentile of 109 public health & general preventive medicine providers in California.
See all public health & general preventive medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WegovySemaglutide | 57 | $70,350 |
| MounjaroTirzepatide | 67 | $67,836 |
| OzempicSemaglutide | 66 | $63,711 |
| EliquisApixaban | 12 | $10,057 |
| Metformin Hcl ErMetformin Hcl | 60 | $1,617 |
| Naltrexone Hcl | 34 | $1,172 |
| Rosuvastatin Calcium | 51 | $817 |
| Levothyroxine Sodium | 21 | $471 |
| Bupropion XlBupropion Hcl | 11 | $256 |
| Losartan Potassium | 16 | $223 |
| Atorvastatin Calcium | 19 | $179 |
| Lisinopril | 19 | $173 |
| Omeprazole | 15 | $151 |
| Amlodipine Besylate | 21 | $142 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 13 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskWegovy, Ozempic | $176 | $134,061123 claims |
| Lilly USA, LLCMounjaro | $118 | $67,83667 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 109 public health & general preventive medicine providers in California.
Other public health & general preventive medicine in San Marcos
- Steven GalsonThousand Oaks$594K
- Ryan ZaneSan Bernardino$97K
- Ross MillerBeverly Hills$65K
- Daniel CosgroveIndian Wells$61K
- Philp DarneySan Francisco$13K
- Karen StuderLoma Linda$9K
- George RutherfordSan Francisco$9K
- Serena TonstadLoma Linda$5K
- Michael Criquila Jolla$3K
- Douglas FryeLos Angeles$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.